comparemela.com

Latest Breaking News On - Remo panaccione - Page 1 : comparemela.com

Johnson & Johnson shares positive phase 3 results for Tremfya versus Stelara in Crohn s disease

The GALAXI programme comprises three trials evaluating the IL-23 inhibitor in the IBD condition

Remo panaccioneDavid leeUniversity of calgaryEuropean medicines agency

Remo Panaccione, MD: GALAXI 2, GALAXI 3 Data for Guselkumab in Crohn s Disease

Remo Panaccione, MD: GALAXI 2, GALAXI 3 Data for Guselkumab in Crohn s Disease
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Remo panaccioneDrug administrationUniversity of calgaryDigestive disease week

GALAXI 1 & 2: Guselkumab Superior to Ustekinumab for Crohn s Disease

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.

United statesDavid leeLinkedin remo panaccioneRemo panaccioneDrug administrationUniversity of calgaryDigestive disease weekJohnson innovative medicineBiologics license applicationGuselkumab therapySeverely active crohnSupplemental biologics license application

GALAXI 2 & 3: Guselkumab Superior to Ustekinumab for Crohn s Disease

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.

United statesRemo panaccioneLinkedin remo panaccioneDavid leeUniversity of calgaryDrug administrationDigestive disease weekJohnson innovative medicineBiologics license applicationGuselkumab therapySeverely active crohnSupplemental biologics license application

Sequence Study of Risankizumab vs Ustekinumab in CD

David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.

Marla dubinskyDavid rubinMiguel regueiroRemo panaccioneSara horstCrohn x27s diseaseIl 12Il 23First line treatment

vimarsana © 2020. All Rights Reserved.